Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Hematology

Identifying Your Specific Subtype

At a Glance

Castleman disease is divided into localized Unicentric (UCD) and widespread Multicentric (MCD) forms. Identifying your specific subtype—whether driven by the HHV-8 virus, POEMS syndrome, or idiopathic (iMCD)—is the most critical step in determining your treatment plan and prognosis.

Castleman disease is not one single condition, but a family of related disorders. Identifying your specific subtype is the most important step in your journey, as it dictates your treatment plan, your prognosis, and how your medical team will monitor your health [1][2].

The Primary Division: UCD vs. MCD

The first distinction your doctor will make is whether the disease is localized or widespread.

  • Unicentric Castleman Disease (UCD): This subtype involves only one area of lymph nodes (for example, just in your neck or just in your chest) [3][4]. UCD is usually “silent,” meaning it doesn’t cause body-wide symptoms like fever. Because it is localized, surgical removal of the affected node is often a complete cure [5][6].
  • Multicentric Castleman Disease (MCD): This involves multiple lymph node regions throughout the body [3][6]. Unlike UCD, MCD usually causes systemic (body-wide) inflammation, making you feel like you have a persistent flu [6][7].

The Three Faces of Multicentric CD

If you have MCD, your doctor must determine what is “driving” the disease. There are three main categories:

  1. HHV-8-Associated MCD: This is caused by an infection with Human Herpesvirus-8 (HHV-8) [8][9]. The virus highjacks your immune cells and forces them to produce their own version of IL-6 (viral IL-6), which triggers the disease [8][10]. This subtype requires specific antiviral or chemotherapy treatments [11][12].
  2. POEMS-Associated MCD: This occurs alongside POEMS syndrome, a rare blood disorder [13][14]. POEMS stands for Polyneuropathy (nerve pain or numbness), Organomegaly (enlarged organs), Endocrinopathy (hormone issues), Monoclonal protein (an abnormal blood protein), and Skin changes. It is driven by an underlying growth of plasma cells and is often identified by high levels of a protein called VEGF [13][15].
  3. Idiopathic MCD (iMCD): “Idiopathic” means the cause is currently unknown (HHV-8 is negative) [16][17]. This is the most common form of multicentric disease and is the focus of most modern research [18][19].

Deep Dive: iMCD Subtypes

Even within iMCD, there are different “flavors” of the disease that behave differently:

  • iMCD-NOS (Not Otherwise Specified): This is the “classic” form of multicentric disease. While it causes inflammation and flares, it is often managed effectively with long-term medication [20][21].
  • iMCD-TAFRO: This is a more aggressive and severe variant [22][23]. It is named after the five symptoms that define it:
    • T: Thrombocytopenia (low blood platelets, causing bruising) [24].
    • A: Anasarca (severe body-wide swelling and fluid buildup) [24].
    • F: Fever (systemic inflammation) [24].
    • R: Reticulin fibrosis (scarring in the bone marrow) or Renal dysfunction (kidney issues) [24].
    • O: Organomegaly (enlarged liver or spleen) [24].

Risk Stratification: The iMCD-IPI

To help predict how your disease might behave, doctors use a “scorecard” called the iMCD-International Prognostic Index (iMCD-IPI) [25]. You receive points based on:

  • Age: Being over 40 years old [25].
  • Severity: Having very low hemoglobin (anemia), fluid around the lungs, or an enlarged liver/spleen [25].
  • Cell Type: Having the “plasma cell” variant under the microscope [25].

A higher score suggests a more “high-risk” disease that may require more intensive or immediate treatment to get under control [25][26]. Your score helps your doctor decide how “aggressively” to fight back from day one.

Common questions in this guide

What is the difference between UCD and MCD?
Unicentric Castleman disease (UCD) affects only one area of lymph nodes and is often cured with surgery. Multicentric Castleman disease (MCD) involves multiple lymph node regions throughout the body and usually causes widespread symptoms like fever, fatigue, and systemic inflammation.
What does idiopathic MCD (iMCD) mean?
Idiopathic MCD is the most common form of multicentric Castleman disease. The term 'idiopathic' means that the disease is not caused by the HHV-8 virus or POEMS syndrome, and its exact underlying cause is currently unknown to doctors.
Why is testing for HHV-8 (LANA-1) important?
Testing your lymph node biopsy for the HHV-8 virus is crucial because it identifies HHV-8-associated MCD. This specific subtype is driven by a viral infection and requires targeted antiviral therapies or specific chemotherapy treatments.
What are the warning signs of the iMCD-TAFRO variant?
TAFRO is a severe and aggressive variant of idiopathic MCD. Its symptoms include low blood platelets causing bruising, severe body-wide swelling, persistent fever, kidney issues or bone marrow scarring, and an enlarged liver or spleen.
What is the iMCD-IPI score used for?
The iMCD-International Prognostic Index is a scoring tool doctors use to predict how your disease might behave. It uses factors like your age, symptom severity, and cell type to categorize your risk level and help decide how aggressively to treat the disease.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my disease classified as UCD or MCD, and how does this affect our primary goal for treatment (e.g., surgery vs. long-term medication)?
  2. 2.Do I meet the criteria for the TAFRO subtype? If so, does that change which treatments we should start immediately?
  3. 3.Was my biopsy tested for HHV-8 (LANA-1)? Knowing this is essential for choosing the right therapy.
  4. 4.Based on my age, lab results, and symptoms, what is my iMCD-IPI score, and how does that categorize my risk level?
  5. 5.Are there any specific markers in my blood, like VEGF or IL-6, that we should be tracking regularly?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (26)
  1. 1

    Clinical Presentation, Treatment, and Outcomes of 28 Patients With Castleman Disease: A Retrospective Analysis of an Italian Cohort.

    Cristinelli C, Merli M, Lucioni M, et al.

    EJHaem 2025; (6(6)):e70158 doi:10.1002/jha2.70158.

    PMID: 41210897
  2. 2

    Five biopsies, one diagnosis: challenges in idiopathic multicentric Castleman disease.

    Semenchuk J, Merchant A, Sakhdari A, Kukreti V

    BMJ case reports 2020; (13(11)) doi:10.1136/bcr-2020-236654.

    PMID: 33229481
  3. 3

    Challenging diagnosis: unusual presentation of Unicentric Castleman disease-a case report.

    Janoud OK, Alok RE, Amer KA, et al.

    Oxford medical case reports 2025; (2025(2)):omae181 doi:10.1093/omcr/omae181.

    PMID: 39990022
  4. 4

    Complete resection of unicentric Castleman disease in the superior mediastinum: A case report.

    Haro A, Kuramitsu E, Fukuyama Y

    International journal of surgery case reports 2016; (25()):44-7.

    PMID: 27318017
  5. 5

    Pelvic unicentric Castleman's disease mimicking accessory spleen: A rare presentation of Castleman's disease, a case report and literature report.

    Emiru ZA, Getahun AM, Kassie YG, et al.

    International journal of surgery case reports 2025; (129()):111177 doi:10.1016/j.ijscr.2025.111177.

    PMID: 40106952
  6. 6

    Multicentric Castleman Disease: A Case Report of an Arab Female.

    Mansour MK, Zayat AS

    Cureus 2024; (16(10)):e71112 doi:10.7759/cureus.71112.

    PMID: 39525135
  7. 7

    A retrospective study of 44 patients with head and neck Castleman's disease.

    Wang T, Chen X, Chen W, et al.

    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2022; (279(5)):2625-2630 doi:10.1007/s00405-021-07065-0.

    PMID: 34480599
  8. 8

    Advances in KSHV Research: Molecular Pathogenesis, Immune Evasion, and Evolving Therapeutic Horizon.

    Nasir MW, Gao Y

    Journal of medical virology 2025; (97(11)):e70695 doi:10.1002/jmv.70695.

    PMID: 41217111
  9. 9

    Kaposi sarcoma-associated herpesvirus/human herpesvirus 8-associated lymphoproliferative disorders.

    Oksenhendler E, Boutboul D, Galicier L

    Blood 2019; (133(11)):1186-1190 doi:10.1182/blood-2018-11-852442.

    PMID: 30610029
  10. 10

    Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Thymidine Kinase (ORF21) by X-Box Binding Protein 1.

    Wang V, Davis DA, Deleage C, et al.

    Journal of virology 2020; (94(5)) doi:10.1128/JVI.01555-19.

    PMID: 31801863
  11. 11

    Severe polyneuropathy in HIV-negative human herpesvirus 8-associated multicentric Castleman disease successfully treated with rituximab and liposomal doxorubicin.

    Takahashi S, Yoshihara K, Fujii T, et al.

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2026; (32(4)):102934 doi:10.1016/j.jiac.2026.102934.

    PMID: 41720336
  12. 12

    Successful outcome in a case of idiopathic multicentric Castleman disease with atypical lymphadenopathy and kidney injury: Diagnostic challenges and treatment approach-Case report.

    Yalikun D, Zhuang J, Lei W, et al.

    SAGE open medical case reports 2024; (12()):2050313X241240097 doi:10.1177/2050313X241240097.

    PMID: 38559411
  13. 13

    POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management.

    Dispenzieri A

    American journal of hematology 2021; (96(7)):872-888 doi:10.1002/ajh.26240.

    PMID: 34000085
  14. 14

    POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management.

    Dispenzieri A

    American journal of hematology 2019; (94(7)):812-827 doi:10.1002/ajh.25495.

    PMID: 31012139
  15. 15

    POEMS Syndrome: Diagnosis and Investigative Work-up.

    Dispenzieri A, Kourelis T, Buadi F

    Hematology/oncology clinics of North America 2018; (32(1)):119-139 doi:10.1016/j.hoc.2017.09.010.

    PMID: 29157614
  16. 16

    Multicentric Castlemans disease. Symptoms, diagnostics and therapy.

    Adam Z, Řehák Z, Adamová Z, et al.

    Vnitrni lekarstvi 2022; (68(1)):41-53.

    PMID: 35459346
  17. 17

    Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease.

    Goodman AM, Jeong AR, Phillips A, et al.

    European journal of haematology 2021; (107(6)):642-649 doi:10.1111/ejh.13702.

    PMID: 34431136
  18. 18

    Castleman disease.

    Carbone A, Borok M, Damania B, et al.

    Nature reviews. Disease primers 2021; (7(1)):84 doi:10.1038/s41572-021-00317-7.

    PMID: 34824298
  19. 19

    Updates on the diagnosis and management of multicentric Castleman disease.

    Wu YJ, Su KY

    Tzu chi medical journal 2021; (33(1)):22-28 doi:10.4103/tcmj.tcmj_15_20.

    PMID: 33505874
  20. 20

    Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.

    Gao YH, Liu YT, Zhang MY, et al.

    British journal of haematology 2024; (204(5)):1830-1837 doi:10.1111/bjh.19334.

    PMID: 38356434
  21. 21

    Overview of Castleman disease.

    Dispenzieri A, Fajgenbaum DC

    Blood 2020; (135(16)):1353-1364 doi:10.1182/blood.2019000931.

    PMID: 32106302
  22. 22

    TAFRO Syndrome: A Syndrome or a Subtype of Multicentric Castleman Disease?

    Takai K

    Biomedicines 2024; (12(3)) doi:10.3390/biomedicines12030652.

    PMID: 38540266
  23. 23

    TAFRO Syndrome.

    Igawa T, Sato Y

    Hematology/oncology clinics of North America 2018; (32(1)):107-118 doi:10.1016/j.hoc.2017.09.009.

    PMID: 29157612
  24. 24

    Thrombotic microangiopathy on kidney biopsy in a patient with TAFRO syndrome.

    Ozeki T, Tsuji M, Yamamoto J, et al.

    CEN case reports 2018; (7(2)):243-247 doi:10.1007/s13730-018-0338-x.

    PMID: 29766467
  25. 25

    A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.

    Yu L, Shi M, Cai Q, et al.

    The oncologist 2020; (25(11)):963-973 doi:10.1634/theoncologist.2019-0986.

    PMID: 32852137
  26. 26

    [Sequential treatment with siltuximab and tocilizumab for childhood idiopathic multicentric Castleman disease: a case report].

    Yi P, Zhang XX, Tang T, et al.

    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2025; (27(5)):613-617 doi:10.7499/j.issn.1008-8830.2412050.

    PMID: 40462437

This page explains Castleman disease subtypes for educational purposes only. Always consult your hematologist or oncologist for an official diagnosis and a treatment plan tailored to your specific disease variant.

Get notified when new evidence is published on Castleman disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.